ScreenerHero

STRO Sutro Biopharma, Inc.

NAS · US · Healthcare · Biotechnology · sutrobio.com
14.66USD+1.45%Mkt Cap: 243.08M $P/E: —

Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, Xpr…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap243.08M USD
Enterprise Value86.03M USD
Revenue (TTM)45.70M USD
Gross Profit-99.04M USD
Net Income (TTM)-191.09M USD
Revenue/Share3.92 USD
Last Price14.66 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees128
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.33
PEG—
EV/EBITDA-0.68
EV/Revenue1.88
P/S5.24
P/B-2.32
EPS (TTM)-16.51
EPS (Forward)-6.21
52W Range
7.15020% of range43.85
52W High43.85 USD
52W Low7.150 USD
Profitability
Gross Margin-216.71%
Oper. Margin-301.73%
EBITDA Margin-275.25%
Profit Margin-186.45%
ROE144.27%
ROA-109.93%
Growth
Revenue Growth-84.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-177.23M USD
CapEx (TTM)1.70M USD
FCF Margin-220.46%
FCF Yield-41.45%
Net Debt-153.56M USD
Net Debt/EBITDA1.22
Balance Sheet
Debt/Equity-0.12
Current Ratio3.32
Quick Ratio3.22
Book Value/Sh-6.23 USD
Cash/Share9.91 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateDec 3, 2025
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)47.23 USD
Upside (mean)+222.2%
Target Range10.00 USD – 61.00 USD
10.00+222.2% to mean61.00
# Analysts13
Ownership
Shares Out.16.58M
Float10.76M
Insiders2.26%
Institutions98.91%
Short Interest
Short Ratio7.4d
Short % Float12.56%
Short % Out.12.52%
Shares Short2.08M
Short (prev mo.)1.86M
Technical
SMA 5020.03 (-26.8%)
SMA 20023.00 (-36.3%)
Beta1.50
S&P 52W Chg16.45%
Avg Vol (30d)252.98K
Avg Vol (10d)231.67K
Technical Indicators
RSI (14)26.9
MACD-1.6742
MACD Signal-1.7685
MACD Hist.+0.0943
BB Upper19.30 USD
BB Middle16.42 USD
BB Lower13.54 USD
BB Width35.11%
ATR (14)1.249 USD
Vol Ratio (20d)0.87x